Cytokine production in anorexia nervosa.

Abstract:

:The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-35%, p = 0.058) to release IL-3-LA by PBMCs of AN patients was found, as compared with cells of the control group. IL-1 production, either spontaneous or after stimulation with lipopolysaccharide (LPS), did not differ significantly between AN patients and healthy subjects. The lessened capacity to produce IL-2 was accompanied by an enhanced stimulatory activity of the patient sera on the production of this cytokine by PBMCs of healthy subjects. It is therefore suggested that the serum of AN patients contains a stimulatory factor or factors for cytokine production that compensates for the lower production of cytokines by AN PBMCs. Such a compensatory mechanism may explain why AN patients do not have an higher susceptibility to infections.

journal_name

Clin Neuropharmacol

authors

Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

doi

10.1097/00002826-199306000-00007

subject

Has Abstract

pub_date

1993-06-01 00:00:00

pages

237-43

issue

3

eissn

0362-5664

issn

1537-162X

journal_volume

16

pub_type

杂志文章
  • Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

    abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013e31827db49b

    authors: Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

    更新日期:2013-01-01 00:00:00

  • Clinical pharmacology and mechanism of action of zonisamide.

    abstract::Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/wnf.0b013e3180413d7d

    authors: Biton V

    更新日期:2007-07-01 00:00:00

  • Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

    abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000240941.13876.5E

    authors: Palakurthi HB,Parvin MM,Kaplan S

    更新日期:2007-01-01 00:00:00

  • Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

    abstract::Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200111000-00006

    authors: Giménez-Roldán S,Esteban EM,Mateo D

    更新日期:2001-11-01 00:00:00

  • EEG changes induced by oxiracetam on diazepam-medicated volunteers.

    abstract::The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Giaquinto S,Nolfe G,Vitali S

    更新日期:1986-01-01 00:00:00

  • Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

    abstract::The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318223421f

    authors: da Rocha FF,Correa H

    更新日期:2011-07-01 00:00:00

  • An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

    abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/WNF.0b013e3181f8d501

    authors: Anand R,Geffen Y,Vasile D,Dan I

    更新日期:2010-11-01 00:00:00

  • Low-dose bromocriptine in the early phases of Parkinson's disease.

    abstract::The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Tolosa E,Blesa R,Bayes A,Forcadell F

    更新日期:1987-04-01 00:00:00

  • Acute spinal cord injury, part I: pathophysiologic mechanisms.

    abstract::Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Sp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200109000-00002

    authors: Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

    更新日期:2001-09-01 00:00:00

  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.

    abstract:BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e318206785a

    authors: Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

    更新日期:2011-01-01 00:00:00

  • Kleptomania after head trauma: two case reports and combination treatment strategies.

    abstract::The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000144042.66342.d3

    authors: Aizer A,Lowengrub K,Dannon PN

    更新日期:2004-09-01 00:00:00

  • Antiepileptic drugs in posttraumatic stress disorder.

    abstract::Antiepileptic drugs might be effective in the treatment of patients with Posttraumatic Stress Disorder, a condition with unmet pharmacologic needs. We review the literature on the efficacy and tolerability of antiepileptic drugs in Posttraumatic Stress Disorder, both case reports and open studies, as well as controlle...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200207000-00006

    authors: Iancu I,Rosen Y,Moshe K

    更新日期:2002-07-01 00:00:00

  • Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.

    abstract::Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00002826-199417001-00002

    authors: Gagiano CA,Hart GA,Bodemer W,Schall R

    更新日期:1994-01-01 00:00:00

  • Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene.

    abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000024

    authors: Oravivattanakul S,Abboud H,Fernandez H,Itin I

    更新日期:2014-03-01 00:00:00

  • Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.

    abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199508000-00009

    authors: Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

    更新日期:1995-08-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • The management of coexisting depression in patients with dementia: potential of calcium channel antagonists.

    abstract::Depression frequently coexists with dementia, although in many cases the depression is not recognized clinically. Depression represents a major additional burden in dementia, not only for the patients but also for families, caregivers, and, economically, society as a whole. However, depression in patients with dementi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199702000-00003

    authors: De Vry J,Fritze J,Post RM

    更新日期:1997-02-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Gabapentin treatment for muscle cramps: an open-label trial.

    abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200001000-00008

    authors: Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

    更新日期:2000-01-01 00:00:00

  • United States experience and perspectives with trazodone.

    abstract::In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00002826-198901001-00003

    authors: Fabre LF

    更新日期:1989-01-01 00:00:00

  • Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.

    abstract:OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000058

    authors: Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

    更新日期:2015-01-01 00:00:00

  • Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.

    abstract:OBJECTIVES:IPX066 is an oral, extended-release capsule formulation of carbidopa-levodopa (CD-LD) available in 4 strengths. The goals of this investigation were to assess the dose proportionality of IPX066 and to study the effects of a high-fat, high-calorie meal and of sprinkling the capsule contents on applesauce on t...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000126

    authors: Yao HM,Hsu A,Gupta S,Modi NB

    更新日期:2016-01-01 00:00:00

  • Effect of midazolam on memory during fiberoptic gastroscopy under conscious sedation.

    abstract:OBJECTIVE:As the fiberoptic gastroscopy using midazolam is being in widespread use, the exact nature of midazolam on memory should be clarified. We intended to examine whether midazolam causes selective anterograde amnesia and what impact it has on other aspects of memory and general cognitive function. METHODS:We rec...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000067

    authors: Hong YJ,Jang EH,Hwang J,Roh JH,Kwon M,Lee D,Lee JH

    更新日期:2015-03-01 00:00:00

  • Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

    abstract:OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000180228.77802.32

    authors: Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

    更新日期:2005-09-01 00:00:00

  • Memantine Rescues Neurosyphilis-Related Schizophrenic-like Features and Cognitive Deficit.

    abstract:OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000347

    authors: Chen WC,Wang HY,Chen PA,Chen IC,Chen YC

    更新日期:2019-07-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

    abstract::The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198604000-00005

    authors: Rascol A,Montastruc JL,Rascol O,Senard JM

    更新日期:1986-01-01 00:00:00

  • Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates.

    abstract:OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000248

    authors: Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

    更新日期:2017-11-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00